New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
Retrieved on:
Wednesday, May 31, 2023
Health, Science, Pharmaceutical, Research, Clinical Trials, Pros, CT, Bronchoscopic lung volume reduction, MSU, Acid erosion, RCT, Oswestry Disability Index, Quality of life, Methotrexate, Patient, Data, MIRROR, HAQ, Randomized controlled trial, DECT, Bone remodeling, Disease, Medical imaging, Rheumatology, Pain, Gout
Presentations are part of expert discussions at the EULAR European Congress of Rheumatology , May 31 - June 3, 2023, in Milan.
Key Points:
- Presentations are part of expert discussions at the EULAR European Congress of Rheumatology , May 31 - June 3, 2023, in Milan.
- Data presented from Horizon’s MIRROR randomized controlled trial (RCT), which evaluated KRYSTEXXA in combination with methotrexate for uncontrolled gout, provide further evidence of the impact of therapy on patient-reported outcomes (PROs), urate depletion and bone remodeling.
- “Uncontrolled gout is far more painful and dangerous than most people know,” said Brian LaMoreaux, M.D., M.S., senior medical director, Horizon.
- Bone erosion remodeling after depletion of monosodium urate deposition with intensive urate-lowering with pegloticase in patients with uncontrolled gout: MIRROR RCT dual-energy CT findings (POS0514)